Sana Biotechnology Appoints Brian Piper As New CFO To Support Upcoming Clinical Readouts For SC451 In Type 1 Diabetes And SG293 In B-Cell Disease

Sana Biotechnology, Inc., a company dedicated to transforming patient care through engineered cells, has announced the appointment of Brian Piper as Executive Vice President and Chief Financial Officer. Piper brings more than 25 years of financial and operational experience in the biopharmaceutical sector, having held key leadership roles across several organizations. Before joining Sana, he served as CFO of Scorpion Therapeutics and later of Antares Therapeutics, the company formed following Scorpion’s acquisition and subsequent spin-off. His extensive background positions him to play an important role as Sana continues to advance its portfolio of cell and gene therapy programs.

Steve Harr, President and Chief Executive Officer of Sana, stated that Piper’s arrival marks an important addition to the Company’s leadership team. Harr emphasized Piper’s strengths in capital formation, disciplined financial strategy, and operational leadership. Over the next 12 to 18 months, Sana expects to generate initial clinical data from SC451 for the treatment of type 1 diabetes and from SG293 for a B-cell–related condition. These early results are anticipated to provide valuable insights into the Company’s therapeutic platforms and serve as major value-defining milestones. Harr noted that Sana’s programs in type 1 diabetes and its in vivo CAR T platform continue to gain strong momentum, and Piper’s leadership will be essential as the Company advances its therapies, supports long-term value creation, and works toward delivering transformative treatments to patients.

Piper’s professional experience includes serving as CFO of Scorpion Therapeutics until its acquisition by Eli Lilly in 2025, after which he became CFO of Antares Therapeutics. He previously held the same role at Prelude Therapeutics and at Aevi Genomic Medicine. Earlier in his career, he spent 13 years at Shire Pharmaceuticals, where he held senior roles in investor relations, corporate venture capital, and broader financial operations. He began his career at Celera Genomics and Otsuka Pharmaceuticals. Piper holds an M.B.A. from the University of Maryland and a B.B.A. from the University of Notre Dame.

Reflecting on his new role, Piper said he is excited to join Sana at a moment of significant progress for the Company. He highlighted the promising clinical potential demonstrated by Sana’s hypoimmune-modified pancreatic islet cells in type 1 diabetes, as well as the Company’s plans to initiate clinical development of its in vivo CAR T platform. Piper expressed enthusiasm about working closely with Sana’s teams to maintain a strong financial foundation, support operational excellence, and apply disciplined capital allocation strategies that further the Company’s mission of delivering meaningful patient impact while creating long-term value for shareholders.